{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:39:56Z","timestamp":1790959196066,"version":"4.1.0"},"reference-count":218,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00298","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T04:49:05Z","timestamp":1583297345000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":81,"title":["Management of Cancer Cachexia: Attempting to Develop New Pharmacological Agents for New Effective Therapeutic Options"],"prefix":"10.3389","volume":"10","author":[{"given":"Gioacchino P.","family":"Marceca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Londhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Calore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia","volume":"10","author":"Fearon","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.trecan.2018.10.001","article-title":"Cancer cachexia: more than skeletal muscle wasting","volume":"4","author":"Schmidt","year":"2018","journal-title":"Trends Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/SPC.0000000000000382","article-title":"Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition","volume":"12","author":"Pin","year":"2018","journal-title":"Curr Opin Support Palliat Care"},{"key":"B4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin Nutr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/bjc.1993.126","article-title":"Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia","volume":"67","author":"Smith","year":"1993","journal-title":"Br J Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nrc927","article-title":"Cachexia in cancer patients","volume":"2","author":"Tisdale","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/MCO.0000000000000048","article-title":"Coming back: autophagy in cachexia","volume":"17","author":"Penna","year":"2014","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/ejcn.2016.96","article-title":"Key determinants of energy expenditure in cancer and implications for clinical practice","volume":"70","author":"Purcell","year":"2016","journal-title":"Eur J Clin Nutr"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3945\/ajcn.116.140434","article-title":"Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy","volume":"105","author":"Vazeille","year":"2017","journal-title":"Am J Clin Nutr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature13528","article-title":"Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia","volume":"513","author":"Kir","year":"2014","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cmet.2014.06.011","article-title":"A switch from white to brown fat increases energy expenditure in cancer-associated cachexia","volume":"20","author":"Petruzzelli","year":"2014","journal-title":"Cell Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cmet.2011.12.018","article-title":"FAT SIGNALS - lipases and lipolysis in lipid metabolism and signaling","volume":"15","author":"Zechner","year":"2012","journal-title":"Cell Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.tem.2014.03.002","article-title":"Lipolysis in lipid turnover, cancer cachexia, and obesity-induced insulin resistance","volume":"25","author":"Arner","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/jcsm.12402","article-title":"Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review","volume":"10","author":"Anker","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","article-title":"ESPEN guidelines on nutrition in cancer patients","volume":"36","author":"Arends","year":"2017","journal-title":"Clin Nutr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","article-title":"Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group","volume":"69","author":"Dewys","year":"1980","journal-title":"Am J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6391","DOI":"10.1158\/1078-0432.CCR-09-0877","article-title":"Gender disparities in metastatic colorectal cancer survival","volume":"15","author":"Hendifar","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1133S","DOI":"10.3945\/ajcn.2010.28608C","article-title":"Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis","volume":"91","author":"Baracos","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"B20","doi-asserted-by":"publisher","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1357-2725(02)00251-0","article-title":"Cancer cachexia: the molecular mechanisms","volume":"35","author":"Argil\u00e9s","year":"2003","journal-title":"Int J Biochem Cell Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/bjc.2012.144","article-title":"Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma","volume":"106","author":"Prado","year":"2012","journal-title":"Br J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3945\/ajcn.113.060228","article-title":"Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?","volume":"98","author":"Prado","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"B24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.critrevonc.2014.10.014","article-title":"Cachexia: a preventable comorbidity of cancer. A T.A.R.G.E.T. approach","volume":"94","author":"Muscaritoli","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e000097","DOI":"10.1136\/bmjgast-2016-000097","article-title":"Cachexia in cancer: what is in the definition?","volume":"3","author":"Vanhoutte","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/bjc.2011.323","article-title":"Is there a genetic cause for cancer cachexia? - a clinical validation study in 1797 patients","volume":"105","author":"Solheim","year":"2011","journal-title":"Br J Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/jcsm.12138","article-title":"New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss","volume":"8","author":"Johns","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B28","doi-asserted-by":"publisher","first-page":"S460","DOI":"10.1067\/mai.2003.108","article-title":"2. Cytokines and chemokines","volume":"111","author":"Borish","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrc2507","article-title":"Cytokines and their relationship to the symptoms and outcome of cancer","volume":"8","author":"Seruga","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1096\/fj.06-7227rev","article-title":"Resolution of inflammation: state of the art, definitions and terms","volume":"21","author":"Serhan","year":"2007","journal-title":"FASEB J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1186\/s12885-018-5080-4","article-title":"Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials","volume":"18","author":"Advani","year":"2018","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/320584a0","article-title":"Cachectin and tumour necrosis factor as two sides of the same biological coin","volume":"320","author":"Beutler","year":"1986","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0092-8674(87)90028-6","article-title":"Tumors secreting human TNF\/cachectin induce cachexia in mice","volume":"50","author":"Oliff","year":"1987","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nri1184","article-title":"Signalling pathways of the TNF superfamily: a double-edged sword","volume":"3","author":"Aggarwal","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1126\/science.289.5488.2363","article-title":"NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia","volume":"289","author":"Guttridge","year":"2000","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2337\/diabetes.51.5.1319","article-title":"Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory","volume":"51","author":"Ruan","year":"2002","journal-title":"Diabetes"},{"key":"B37","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1096\/fasebj.12.10.871","article-title":"Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha","volume":"12","author":"Li","year":"1998","journal-title":"FASEB J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"R1165","DOI":"10.1152\/ajpregu.2000.279.4.R1165","article-title":"NF-\u03baB mediates the protein loss induced by TNF-\u03b1 in differentiated skeletal muscle myotubes","volume":"279","author":"Li","year":"2000","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1172\/JCI200420174","article-title":"Cancer cachexia is regulated by selective targeting of skeletal muscle gene products","volume":"114","author":"Acharyya","year":"2004","journal-title":"J Clin Invest"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1096\/fj.06-7537com","article-title":"TNF-related weak inducer of apoptosis. (TWEAK) is a potent skeletal muscle-wasting cytokine","volume":"21","author":"Dogra","year":"2007","journal-title":"FASEB J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1083\/jcb.200909117","article-title":"The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice","volume":"188","author":"Mittal","year":"2010","journal-title":"J Cell Biol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1172\/JCI115767","article-title":"Evidence for the involvement of interleukin 6 in experimental cancer cachexia","volume":"89","author":"Strassmann","year":"1992","journal-title":"J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e24650","DOI":"10.1371\/journal.pone.0024650","article-title":"The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the ApcMin\/mouse","volume":"6","author":"White","year":"2011","journal-title":"PLoS ONE"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1172\/JCI116816","article-title":"Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo","volume":"92","author":"Strassmann","year":"1993","journal-title":"J Clin Invest"},{"key":"B45","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1210\/er.21.3.313","article-title":"Leukemia-inhibitory factor-neuroimmune modulator of endocrine function","volume":"21","author":"Auernhammer","year":"2000","journal-title":"Endocr Rev"},{"key":"B46","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nature05993","article-title":"p53 regulates maternal reproduction through LIF","volume":"450","author":"Hu","year":"2007","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1073\/pnas.86.15.5948","article-title":"Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor","volume":"86","author":"Metcalf","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"B48","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1349-7006.1997.tb00421.x","article-title":"In vivo effect of recombinant human leukemia inhibitory factor in primates","volume":"88","author":"Akiyama","year":"1997","journal-title":"Jpn J Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"19976","DOI":"10.1074\/jbc.M115.638411","article-title":"A key role for leukemia inhibitory factor in C26 cancer cachexia","volume":"290","author":"Seto","year":"2015","journal-title":"J Biol Chem"},{"key":"B50","doi-asserted-by":"publisher","first-page":"121221","DOI":"10.1172\/jci.insight.121221","article-title":"Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin","volume":"3","author":"Arora","year":"2018","journal-title":"JCI Insight"},{"key":"B51","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1056\/NEJM198303103081002","article-title":"Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen. (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever","volume":"308","author":"Baracos","year":"1983","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"R659","DOI":"10.1152\/ajpregu.1989.256.3.R659","article-title":"Cachectin\/TNF or IL-1 alpha induces cachexia with redistribution of body proteins","volume":"256","author":"Fong","year":"1989","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B53","first-page":"415","article-title":"Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia","volume":"51","author":"Gelin","year":"1991","journal-title":"Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1084\/jem.20111020","article-title":"Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis","volume":"208","author":"Braun","year":"2011","journal-title":"J Exp Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1158\/0008-5472.CAN-11-2739","article-title":"Targeting protein synthesis in a Myc\/mTOR-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival","volume":"72","author":"Robert","year":"2012","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jaci.2010.11.050","article-title":"Interleukins, from 1 to 37, and interferon-\u03b3: Receptors, functions, and roles in diseases","volume":"127","author":"Akdis","year":"2011","journal-title":"J Aller Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/ijc.2910400621","article-title":"Enhanced metastases of a mouse carcinoma after in vitro treatment with murine interferon gamma","volume":"40","author":"Ramani","year":"1987","journal-title":"Int J Cancer"},{"key":"B58","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.4049\/jimmunol.153.10.4604","article-title":"IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma. (TS\/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS\/A cells","volume":"153","author":"Ferrantini","year":"1994","journal-title":"J Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/1043-4666(92)90065-Y","article-title":"Interferon-\u03b3, more of a cachectin than tumor necrosis factor","volume":"4","author":"Billiau","year":"1992","journal-title":"Cytokine"},{"key":"B60","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/ijc.2910490115","article-title":"Severe cachexia in mice inoculated with interferon-gamma-producing tumor cells","volume":"49","author":"Matthys","year":"1991","journal-title":"Int J Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/0277-5379(91)90483-T","article-title":"Anti-interferon-\u03b3 antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia","volume":"27","author":"Matthys","year":"1991","journal-title":"Eur J Cancer Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/PPO.0b013e318250c001","article-title":"Causes and consequences of MicroRNA dysregulation","volume":"18","author":"Iorio","year":"2012","journal-title":"Cancer J"},{"key":"B63","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/clpt.2012.192","article-title":"Clinical applications for microRNAs in cancer","volume":"93","author":"Nana-Sinkam","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"B64","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of MicroRNA biogenesis, mechanisms of actions, and circulation","volume":"9","author":"O'Brien","year":"2018","journal-title":"Front Endocrinol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccr.2014.03.007","article-title":"Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis","volume":"25","author":"Zhou","year":"2014","journal-title":"Cancer Cell"},{"key":"B66","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1073\/pnas.1402714111","article-title":"Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7","volume":"111","author":"He","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B67","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/jcsm.12403","article-title":"Circulating miR-203 derived from metastatic tissues promotes myopenia in colorectal cancer patients","volume":"10","author":"Okugawa","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B68","doi-asserted-by":"publisher","first-page":"21909","DOI":"10.1074\/jbc.M114.561845","article-title":"Involvement of microRNAs in the regulation of muscle wasting during catabolic conditions","volume":"289","author":"Soares","year":"2014","journal-title":"J Biol Chem"},{"key":"B69","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-018-0899-5","article-title":"Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression","volume":"17","author":"Wu","year":"2018","journal-title":"Mol Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/nri3713","article-title":"Assembly and localization of Toll-like receptor signalling complexes","volume":"14","author":"Gay","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e00184","DOI":"10.1128\/MCB.00184-19","article-title":"The toll-like receptor\/MyD88\/XBP1 signaling axis mediates skeletal muscle wasting during cancer cachexia","volume":"39","author":"Bohnert","year":"2019","journal-title":"Mol Cell Biol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1096\/fj.10-164152","article-title":"Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways","volume":"25","author":"Doyle","year":"2011","journal-title":"FASEB J"},{"key":"B73","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41467-017-00726-x","article-title":"Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat Commun"},{"key":"B74","doi-asserted-by":"publisher","first-page":"18024","DOI":"10.1038\/s41598-018-36626-3","article-title":"Toll-like receptor-4 disruption suppresses adipose tissue remodeling and increases survival in cancer cachexia syndrome","volume":"8","author":"Henriques","year":"2018","journal-title":"Sci Rep"},{"key":"B75","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1158\/0008-5472.CAN-17-3878","article-title":"The TLR7\/8\/9 antagonist IMO-8503 inhibits cancer-induced cachexia","volume":"78","author":"Calore","year":"2018","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"34748","DOI":"10.18632\/oncotarget.26190","article-title":"Leukemia inhibitory factor via the Toll-like receptor 5 signaling pathway involves aggravation of cachexia induced by human gastric cancer-derived 85As2 cells in rats","volume":"9","author":"Terawaki","year":"2018","journal-title":"Oncotarget"},{"key":"B77","doi-asserted-by":"publisher","first-page":"12448","DOI":"10.1073\/pnas.1707925114","article-title":"Blockade of activin type II receptors with a dual anti-ActRIIA\/IIB antibody is critical to promote maximal skeletal muscle hypertrophy","volume":"114","author":"Morvan","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B78","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.coph.2006.11.011","article-title":"The myostatin gene: physiology and pharmacological relevance","volume":"7","author":"Joulia-Ekaza","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1126\/science.1069525","article-title":"Induction of cachexia in mice by systemically administered myostatin","volume":"296","author":"Zimmers","year":"2002","journal-title":"Science"},{"key":"B80","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nature01154","article-title":"Functional improvement of dystrophic muscle by myostatin blockade","volume":"420","author":"Bogdanovich","year":"2002","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","first-page":"E985","DOI":"10.1152\/ajpendo.00531.2006","article-title":"Muscle growth after postdevelopmental myostatin gene knockout","volume":"292","author":"Welle","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B82","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1365-2362.2008.01970.x","article-title":"Muscle myostatin signalling is enhanced in experimental cancer cachexia","volume":"38","author":"Costelli","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"B83","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/sj.gt.3303016","article-title":"Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice","volume":"15","author":"Liu","year":"2008","journal-title":"Gene Ther"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/JOE-08-0549","article-title":"The biology of activin: recent advances in structure, regulation and function","volume":"202","author":"Xia","year":"2009","journal-title":"J Endocrinol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cytogfr.2013.03.003","article-title":"The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis","volume":"24","author":"Hedger","year":"2013","journal-title":"Cytok Growth Factor Rev"},{"key":"B86","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10585-006-9010-5","article-title":"Activin A circulating levels in patients with bone metastasis from breast or prostate cancer","volume":"23","author":"Leto","year":"2006","journal-title":"Clin Exp Metast"},{"key":"B87","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1096\/fj.13-245894","article-title":"Elevated expression of activins promotes muscle wasting and cachexia","volume":"28","author":"Chen","year":"2014","journal-title":"FASEB J"},{"key":"B89","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s13539-011-0049-z","article-title":"Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance","volume":"3","author":"Busquets","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B90","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cmet.2015.11.003","article-title":"PTH\/PTHrP receptor mediates cachexia in models of kidney failure and cancer","volume":"23","author":"Kir","year":"2016","journal-title":"Cell Metab"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00018-010-0465-9","article-title":"Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm","volume":"68","author":"Vilardaga","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"B92","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.febslet.2004.11.042","article-title":"Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human. (SGBS) adipocytes","volume":"579","author":"Bao","year":"2005","journal-title":"FEBS Lett"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1073\/pnas.0308647100","article-title":"Zinc- 2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia","volume":"101","author":"Bing","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B94","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1365-2796.2011.02441.x","article-title":"Adipose zinc-\u03b12-glycoprotein is a catabolic marker in cancer and noncancerous states","volume":"271","author":"Ryd\u00e9n","year":"2012","journal-title":"J Intern Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bbalip.2003.12.004","article-title":"Induction of lipolysis in vitro and loss of body fat in vivo by zinc-\u03b12-glycoprotein","volume":"1636","author":"Russell","year":"2004","journal-title":"Biochim Biophys Acta. Mol Cell Biol Lipids"},{"key":"B96","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.plefa.2005.03.002","article-title":"Effect of eicosapentaenoic acid. (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia","volume":"72","author":"Russell","year":"2005","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"B97","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.febslet.2006.12.047","article-title":"Lipolysis is altered in MHC class I zinc-\u03b12-glycoprotein deficient mice","volume":"581","author":"Rolli","year":"2007","journal-title":"FEBS Lett"},{"key":"B98","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0165-6147(96)10021-3","article-title":"The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states","volume":"17","author":"Argil\u00e9s","year":"1996","journal-title":"Trends Pharmacol Sci"},{"key":"B99","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/MCO.0b013e32833862df","article-title":"Signaling pathways perturbing muscle mass","volume":"13","author":"Glass","year":"2010","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B100","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1038\/emboj.2011.292","article-title":"C\/EBP\u03b2 mediates tumour-induced ubiquitin ligase atrogin1\/MAFbx upregulation and muscle wasting","volume":"30","author":"Zhang","year":"2011","journal-title":"EMBO J"},{"key":"B101","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1172\/JCI68523","article-title":"NF-\u03baB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia","volume":"123","author":"He","year":"2013","journal-title":"J Clin Invest"},{"key":"B102","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semcdb.2016.02.009","article-title":"STAT3 in the systemic inflammation of cancer cachexia","volume":"54","author":"Zimmers","year":"2016","journal-title":"Semin Cell Dev Biol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"622","DOI":"10.15252\/emmm.201607052","article-title":"STAT 3 promotes IFN \u03b3\/ TNF \u03b1-induced muscle wasting in an NF -\u03baB-dependent and IL\u22126-independent manner","volume":"9","author":"Ma","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1097-2765(04)00211-4","article-title":"The IGF-1\/PI3K\/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors","volume":"14","author":"Stitt","year":"2004","journal-title":"Mol Cell"},{"key":"B105","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0092-8674(04)00400-3","article-title":"Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy","volume":"117","author":"Sandri","year":"2004","journal-title":"Cell"},{"key":"B106","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ceb.2017.02.012","article-title":"mTORC1 signaling and the metabolic control of cell growth","volume":"45","author":"Ben-Sahra","year":"2017","journal-title":"Curr Opin Cell Biol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1172\/JCI22324","article-title":"Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting","volume":"115","author":"Song","year":"2005","journal-title":"J Clin Investig"},{"key":"B108","doi-asserted-by":"publisher","first-page":"6670","DOI":"10.1038\/ncomms7670","article-title":"Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy","volume":"6","author":"Milan","year":"2015","journal-title":"Nat Commun"},{"key":"B109","doi-asserted-by":"publisher","first-page":"16260","DOI":"10.1073\/pnas.0607795103","article-title":"PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription","volume":"103","author":"Sandri","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.05.002","article-title":"Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases","author":"Patra","year":"","journal-title":"Semin Cancer Biol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/sj.bjc.6605558","article-title":"High expression of Toll-like receptor 4\/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer","volume":"102","author":"Wang","year":"2010","journal-title":"Br J Cancer"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1016\/j.molimm.2008.01.025","article-title":"Rapamycin suppresses TLR4-triggered IL-6 and PGE2 production of colon cancer cells by inhibiting TLR4 expression and NF-\u03baB activation","volume":"45","author":"Sun","year":"2008","journal-title":"Mol Immunol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/pros.20710","article-title":"The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells","volume":"68","author":"Kundu","year":"2008","journal-title":"Prostate"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/sj.bjc.6604942","article-title":"Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-\u03baB-dependent activation of the urokinase plasminogen activator system","volume":"100","author":"Killeen","year":"2009","journal-title":"Br J Cancer"},{"key":"B115","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.drudis.2012.02.001","article-title":"Myostatin: more than just a regulator of muscle mass","volume":"17","author":"Argil\u00e9s","year":"2012","journal-title":"Drug Discov Today"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1096\/fj.11-191189","article-title":"Cell-type specific regulation of myostatin signaling","volume":"26","author":"Kemaladewi","year":"2012","journal-title":"FASEB J"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.ajpath.2012.12.023","article-title":"Autophagic degradation contributes to muscle wasting in cancer cachexia","volume":"182","author":"Penna","year":"2013","journal-title":"Am J Pathol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3945\/ajcn.113.063859","article-title":"Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients","volume":"98","author":"Tardif","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"B119","doi-asserted-by":"publisher","first-page":"30340","DOI":"10.1038\/srep30340","article-title":"Autophagy is induced in the skeletal muscle of cachectic cancer patients","volume":"6","author":"Aversa","year":"2016","journal-title":"Sci Rep"},{"key":"B120","doi-asserted-by":"publisher","first-page":"26991","DOI":"10.1038\/srep26991","article-title":"Aerobic exercise and pharmacological treatments counteract cachexia by modulating autophagy in colon cancer","volume":"6","author":"Pigna","year":"2016","journal-title":"Sci Rep"},{"key":"B121","doi-asserted-by":"publisher","first-page":"311","DOI":"10.15698\/cst2018.11.163","article-title":"p38\u03b2 MAPK mediates ULK1-dependent induction of autophagy in skeletal muscle of tumor-bearing mice","volume":"2","author":"Liu","year":"2018","journal-title":"Cell Stress Chaperones"},{"key":"B122","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1079\/PNS2001110","article-title":"Pro-inflammatory cytokines and adipose tissue","volume":"60","author":"Coppack","year":"2001","journal-title":"Proc Nutr Soc"},{"key":"B123","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00109-002-0384-9","article-title":"Lipoprotein lipase: structure, function, regulation, and role in disease","volume":"80","author":"Mead","year":"2002","journal-title":"J Mol Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/0925-4439(93)90044-2","article-title":"Increased expression of the mRNA for hormone-sensitive lipase in adipose tissue of cancer patients","volume":"1180","author":"Thompson","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s11745-004-1346-8","article-title":"Effect of cancer cachexia on triacylglycerol\/fatty acid substrate cycling in white adipose tissue","volume":"39","author":"Beck","year":"2004","journal-title":"Lipids"},{"key":"B126","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.2337\/diabetes.51.10.2929","article-title":"Tumor necrosis factor- stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP","volume":"51","author":"Zhang","year":"2002","journal-title":"Diabetes"},{"key":"B127","first-page":"2359","article-title":"Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients","volume":"58","author":"Hirai","year":"1998","journal-title":"Cancer Res"},{"key":"B128","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1054\/bjoc.2001.1992","article-title":"Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor. (LMF)","volume":"85","author":"Islam-Ali","year":"2001","journal-title":"Br J Cancer"},{"key":"B129","doi-asserted-by":"publisher","first-page":"e92966","DOI":"10.1371\/journal.pone.0092966","article-title":"Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation","volume":"9","author":"Tsoli","year":"2014","journal-title":"PLoS ONE"},{"key":"B130","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/35007527","article-title":"Towards a molecular understanding of adaptive thermogenesis","volume":"404","author":"Lowell","year":"2000","journal-title":"Nature"},{"key":"B131","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1042\/cs098001Pa","article-title":"Increased gene expression of brown fat uncoupling protein. (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia","volume":"60","author":"Bing","year":"2000","journal-title":"Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/sj.bjc.6600074","article-title":"Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans","volume":"86","author":"Collins","year":"2002","journal-title":"Br J Cancer"},{"key":"B133","doi-asserted-by":"publisher","first-page":"886","DOI":"10.4161\/15384047.2014.987075","article-title":"Adipose tissue lipolysis and energy metabolism in early cancer cachexia in mice","volume":"16","author":"Kliewer","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"B134","doi-asserted-by":"publisher","first-page":"7153","DOI":"10.1074\/jbc.M109.053942","article-title":"Chronic peroxisome proliferator-activated receptor \u03b3. (PPAR\u03b3) activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes","volume":"285","author":"Petrovic","year":"2010","journal-title":"J Biol Chem"},{"key":"B135","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrendo.2016.136","article-title":"Brown adipose tissue as a secretory organ","volume":"13","author":"Villarroya","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"5066","DOI":"10.1038\/srep05066","article-title":"Parathyroid hormone and parathyroid hormone type-1 receptor accelerate myocyte differentiation","volume":"4","author":"Kimura","year":"2014","journal-title":"Sci Rep"},{"key":"B137","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1158\/0008-5472.CAN-11-3536","article-title":"Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice","volume":"72","author":"Tsoli","year":"2012","journal-title":"Cancer Res"},{"key":"B138","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1128\/MCB.24.7.3057-3067.2004","article-title":"p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene","volume":"24","author":"Cao","year":"2004","journal-title":"Mol Cell Biol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S0306-4522(02)00447-5","article-title":"Induction of uncoupling protein 1 by central interleukin-6 gene delivery is dependent on sympathetic innervation of brown adipose tissue and underlies one mechanism of body weight reduction in rats","volume":"115","author":"Li","year":"2002","journal-title":"Neuroscience"},{"key":"B140","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/S0006-291X(02)00230-9","article-title":"Intracerebroventricular interleukin-6 treatment decreases body fat in rats","volume":"293","author":"Wallenius","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"B141","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature10653","article-title":"Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis","volume":"480","author":"Nguyen","year":"2011","journal-title":"Nature"},{"key":"B142","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ni.2865","article-title":"Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin","volume":"15","author":"Mauer","year":"2014","journal-title":"Nat Immunol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrclinonc.2018.14","article-title":"Bridging the gap: are animal models consistent with clinical cancer cachexia?","volume":"15","author":"Baracos","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.celrep.2019.07.016","article-title":"Modeling human cancer-induced cachexia","volume":"28","author":"Talbert","year":"2019","journal-title":"Cell Rep"},{"key":"B145","doi-asserted-by":"publisher","first-page":"577068","DOI":"10.1016\/j.jneuroim.2019.577068","article-title":"Cachexia induced by Yoshida ascites hepatoma in Wistar rats is not associated with inflammatory response in the spleen or brain","volume":"337","author":"Cernackova","year":"2019","journal-title":"J Neuroimmunol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/embo-reports\/kve064","article-title":"A highly efficient ligand-regulated Cre recombinase mouse line shows that LoxP recombination is position dependent","volume":"2","author":"Vooijs","year":"2001","journal-title":"EMBO Rep"},{"key":"B147","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S1534-5807(03)00399-X","article-title":"Talking about a revolution","volume":"6","author":"Branda","year":"2004","journal-title":"Dev Cell"},{"key":"B148","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11248-017-0018-1","article-title":"Spontaneous recombinase activity of Cre-ERT2 in vivo","volume":"26","author":"Kristianto","year":"2017","journal-title":"Trans Res"},{"key":"B149","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","article-title":"Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice","volume":"7","author":"Hingorani","year":"2005","journal-title":"Cancer Cell"},{"key":"B150","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/jcsm.12225","article-title":"Establishment and characterization of a novel murine model of pancreatic cancer cachexia","volume":"8","author":"Michaelis","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B151","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.devcel.2018.05.026","article-title":"Twist1 activation in muscle progenitor cells causes muscle loss akin to cancer cachexia","volume":"45","author":"Parajuli","year":"2018","journal-title":"Dev Cell"},{"key":"B152","doi-asserted-by":"publisher","first-page":"E743","DOI":"10.1073\/pnas.1714703115","article-title":"Fenofibrate prevents skeletal muscle loss in mice with lung cancer","volume":"115","author":"Goncalves","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B153","doi-asserted-by":"publisher","first-page":"E5677","DOI":"10.3390\/ijms20225677","article-title":"Development and characterization of a genetic mouse model of KRAS mutated colorectal cancer","volume":"20","author":"Maitra","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.ajpath.2015.01.016","article-title":"Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements","volume":"185","author":"Delitto","year":"2015","journal-title":"Am J Pathol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.ajpath.2016.02.009","article-title":"Isolation of pancreatic cancer cells from a patient-derived xenograft model allows for practical expansion and preserved heterogeneity in culture","volume":"186","author":"Pham","year":"2016","journal-title":"Am J Pathol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/MPA.0000000000000843","article-title":"Orthotopic patient-derived pancreatic cancer xenografts engraft into the pancreatic parenchyma, metastasize, and induce muscle wasting to recapitulate the human disease","volume":"46","author":"Go","year":"2017","journal-title":"Pancreas"},{"key":"B157","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1038\/s41467-019-13151-z","article-title":"Publisher correction: the TLR7\/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer","volume":"10","author":"Michaelis","year":"2019","journal-title":"Nat Commun"},{"key":"B158","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.critrevonc.2018.05.006","article-title":"Cancer cachexia: diagnosis, assessment, and treatment","volume":"127","author":"Sadeghi","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/1758834017698643","article-title":"Cancer-induced muscle wasting: latest findings in prevention and treatment","volume":"9","author":"Aversa","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11912-017-0595-4","article-title":"Erratum to: update on management of cancer-related cachexia","volume":"19","author":"Anderson","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/cncr.22944","article-title":"A placebo-controlled double blind trial of etanercept for the cancer anorexia\/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group","volume":"110","author":"Jatoi","year":"2007","journal-title":"Cancer"},{"key":"B162","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1136\/gut.2004.047563","article-title":"Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial","volume":"54","author":"Gordon","year":"2005","journal-title":"Gut"},{"key":"B163","first-page":"292","article-title":"Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia","volume":"14","author":"Mantovani","year":"2010","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1089\/jpm.2012.0146","article-title":"The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study","volume":"15","author":"Yennurajalingam","year":"2012","journal-title":"J Palliat Med"},{"key":"B165","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4103\/2277-9175.179182","article-title":"Pentoxifylline treatment in patients with cancer cachexia: a double-blind, randomized, placebo-controlled clinical trial","volume":"5","author":"Mehrzad","year":"2016","journal-title":"Adv Biomed Res"},{"key":"B166","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1200\/JCO.1995.13.11.2856","article-title":"Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial","volume":"13","author":"Goldberg","year":"1995","journal-title":"J Clin Oncol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.lungcan.2009.06.020","article-title":"A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and\/or poor performance non-small cell lung cancer patients. (N01C9)","volume":"68","author":"Jatoi","year":"2010","journal-title":"Lung Cancer"},{"key":"B168","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1200\/jco.2009.27.15_suppl.3025","article-title":"A phase I, pharmacokinetic. (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer","volume":"27","author":"Clarke","year":"2009","journal-title":"J Clin Oncol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.1200\/jco.2010.28.15_suppl.7622","article-title":"Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer. (NSCLC): results of a phase II randomized, double-blind safety and efficacy trial","volume":"28","author":"Rigas","year":"2010","journal-title":"J Clin Oncol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1200\/JCO.2010.33.9473","article-title":"Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers","volume":"29","author":"Bekaii-Saab","year":"2011","journal-title":"J Clin Oncol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S1470-2045(14)70155-X","article-title":"MABp1, a first-in-class true human antibody targeting interleukin-1\u03b1 in refractory cancers: an open-label, phase 1 dose-escalation and expansion study","volume":"15","author":"Hong","year":"2014","journal-title":"Lancet Oncol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/hed.20662","article-title":"Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract","volume":"30","author":"Lai","year":"2008","journal-title":"Head Neck"},{"key":"B174","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00109-009-0547-z","article-title":"Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia","volume":"88","author":"Mantovani","year":"2010","journal-title":"J Mol Med"},{"key":"B175","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/jco.2012.30.15_suppl.2516","article-title":"Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer","volume":"30","author":"Jameson","year":"2012","journal-title":"J Clin Oncol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/jcsm.12331","article-title":"LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial","volume":"9","author":"Golan","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B177","doi-asserted-by":"publisher","first-page":"E1967","DOI":"10.1210\/jc.2014-1271","article-title":"Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer","volume":"99","author":"Padhi","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004310.pub3","article-title":"Megestrol acetate for treatment of anorexia-cachexia syndrome","author":"Ruiz Garcia","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B179","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1517\/14656560902960162","article-title":"Medroxyprogesterone acetate in the management of cancer cachexia","volume":"10","author":"Madeddu","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"B180","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1002\/cncr.27430","article-title":"Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study","volume":"118","author":"Hiura","year":"2012","journal-title":"Cancer"},{"key":"B181","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia. (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/annonc\/mdx192","article-title":"ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer. (NSCLC) patients with cachexia","volume":"28","author":"Currow","year":"2017","journal-title":"Ann Oncol"},{"key":"B183","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1200\/JCO.2005.05.1847","article-title":"Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group","volume":"24","author":"Strasser","year":"2006","journal-title":"J Clin Oncol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1093\/annonc\/mdq727","article-title":"Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial","volume":"22","author":"Brisbois","year":"2011","journal-title":"Ann Oncol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"1534735419881498","DOI":"10.1177\/1534735419881498","article-title":"The effects of dosage-controlled cannabis capsules on cancer-related cachexia and anorexia syndrome in advanced cancer patients: pilot study","volume":"18","author":"Bar-Sela","year":"2019","journal-title":"Integr Cancer Ther"},{"key":"B186","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1007\/s00520-018-4154-9","article-title":"The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial","volume":"26","author":"Turcott","year":"2018","journal-title":"Support Care Cancer"},{"key":"B187","doi-asserted-by":"publisher","first-page":"6855","DOI":"10.1158\/1078-0432.CCR-04-0373","article-title":"Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients","volume":"10","author":"Lindholm","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B188","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","article-title":"A humanized anti-IL-6 antibody. (ALD518) in non-small cell lung cancer","volume":"11","author":"Bayliss","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"B189","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2007-03-081240","article-title":"Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis","volume":"110","author":"Tai","year":"2007","journal-title":"Blood"},{"key":"B190","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"B191","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.nut.2005.06.003","article-title":"Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy","volume":"22","author":"Gramignano","year":"2006","journal-title":"Nutrition"},{"key":"B192","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clnu.2011.10.005","article-title":"Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib \u00b1 megestrol acetate for patients with cancer-related anorexia\/cachexia syndrome","volume":"31","author":"Madeddu","year":"2012","journal-title":"Clin Nutr"},{"key":"B193","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1152\/physrev.90100.2007","article-title":"Muscle as an endocrine organ: focus on muscle-derived interleukin-6","volume":"88","author":"Pedersen","year":"2008","journal-title":"Physiol Rev"},{"key":"B194","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bone.2015.02.008","article-title":"Skeletal muscle as an endocrine organ: PGC-1\u03b1, myokines and exercise","volume":"80","author":"Schnyder","year":"2015","journal-title":"Bone"},{"key":"B195","doi-asserted-by":"publisher","first-page":"8260742","DOI":"10.1155\/2018\/8260742","article-title":"Myokines as possible therapeutic targets in cancer cachexia","volume":"2018","author":"Manole","year":"2018","journal-title":"J Immunol Res"},{"key":"B196","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1128\/MCB.01307-13","article-title":"An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy","volume":"34","author":"Lach-Trifilieff","year":"2014","journal-title":"Mol Cell Biol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1615\/CritRevOncog.v9.i2.10","article-title":"Cytokine involvement in cancer anorexia\/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms","volume":"9","author":"Mantovani","year":"1998","journal-title":"Crit Rev Oncog"},{"key":"B198","doi-asserted-by":"publisher","first-page":"M48","DOI":"10.1093\/gerona\/56.1.M48","article-title":"The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients","volume":"56","author":"Yeh","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"B199","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/107327481602300212","article-title":"Pharmacy report: megestrol acetate-induced adrenal insufficiency","volume":"23","author":"Nanjappa","year":"2016","journal-title":"Cancer Control"},{"key":"B200","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1159\/000346446","article-title":"Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide","volume":"58","author":"Wen","year":"2012","journal-title":"Chemotherapy"},{"key":"B201","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1159\/000492559","article-title":"Ghrelin as a promising therapeutic option for cancer cachexia","volume":"48","author":"Khatib","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B202","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.tins.2016.12.003","article-title":"Current Understanding of the hypothalamic ghrelin pathways inducing appetite and adiposity","volume":"40","author":"Al Massadi","year":"2017","journal-title":"Trends Neurosci"},{"key":"B203","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/SPC.0000000000000012","article-title":"Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment","volume":"7","author":"Ali","year":"2013","journal-title":"Curr Opin Support Palliat Care"},{"key":"B204","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s13539-014-0159-5","article-title":"Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile","volume":"5","author":"Pietra","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B205","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.12-5-594","article-title":"Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers","volume":"12","author":"Garcia","year":"2007","journal-title":"Oncologist"},{"key":"B206","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2217\/fon-2017-0141","article-title":"The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia","volume":"13","author":"Currow","year":"2017","journal-title":"Fut Oncol"},{"key":"B207","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1152\/physrev.00002.2016","article-title":"From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology","volume":"96","author":"Ligresti","year":"2016","journal-title":"Physiol Rev"},{"key":"B208","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1194\/jlr.M038406","article-title":"Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models","volume":"54","author":"Penna","year":"2013","journal-title":"J Lipid Res"},{"key":"B209","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.cyto.2005.10.002","article-title":"Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine","volume":"32","author":"Kanzaki","year":"2005","journal-title":"Cytokine"},{"key":"B210","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/nm.4093","article-title":"Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia","volume":"22","author":"Fukawa","year":"2016","journal-title":"Nat Med"},{"key":"B211","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.molmet.2019.08.011","article-title":"Metformin prevents the pathological browning of subcutaneous white adipose tissue","volume":"29","author":"Auger","year":"2019","journal-title":"Mol Metab"},{"key":"B212","doi-asserted-by":"publisher","first-page":"djv274","DOI":"10.1093\/jnci\/djv274","article-title":"Preclinical investigation of the novel histone deacetylase inhibitor AR-42 in the treatment of cancer-induced cachexia","volume":"107","author":"Tseng","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"B213","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab"},{"key":"B214","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1242\/jcs.136390","article-title":"HDAC1 activates FoxO and is both sufficient and required for skeletal muscle atrophy","volume":"127","author":"Beharry","year":"2014","journal-title":"J Cell Sci"},{"key":"B215","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3389\/fphys.2017.00508","article-title":"Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics","volume":"8","author":"Gao","year":"2017","journal-title":"Front Physiol"},{"key":"B216","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.intimp.2010.04.027","article-title":"Atorvastatin affects TLR4 clustering via lipid raft modulation","volume":"10","author":"Chansrichavala","year":"2010","journal-title":"Int Immunopharmacol"},{"key":"B217","doi-asserted-by":"publisher","first-page":"6748","DOI":"10.1158\/1078-0432.CCR-12-1149","article-title":"Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer","volume":"18","author":"Adams","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B218","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1158\/2326-6066.CIR-18-0243","article-title":"TLR Stimulation during T-cell activation lowers PD-1 expression on CD8 T cells","volume":"6","author":"Zahm","year":"2018","journal-title":"Cancer Immunol Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00298\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T02:00:27Z","timestamp":1695866427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00298\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":218,"alternative-id":["10.3389\/fonc.2020.00298"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00298","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]},"article-number":"298"}}